UBS Group Issues Pessimistic Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

Kymera Therapeutics (NASDAQ:KYMR) had its price objective lowered by UBS Group from $80.00 to $74.00 in a research report released on Monday, Benzinga reports. UBS Group currently has a buy rating on the stock.

KYMR has been the topic of several other research reports. Guggenheim upped their target price on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday. Leerink Partners reissued an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Monday, September 9th. Leerink Partnrs raised shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. B. Riley increased their price target on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th. Finally, Truist Financial restated a “buy” rating and set a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.93.

Kymera Therapeutics Stock Up 1.3 %

NASDAQ:KYMR opened at $47.07 on Monday. Kymera Therapeutics has a twelve month low of $13.85 and a twelve month high of $53.27. The business has a 50 day moving average price of $46.98 and a two-hundred day moving average price of $40.83.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same quarter last year, the firm earned ($0.90) earnings per share. The firm’s revenue for the quarter was down 20.9% compared to the same quarter last year. On average, research analysts expect that Kymera Therapeutics will post -2.84 EPS for the current year.

Insider Activity

In related news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Values First Advisors Inc. bought a new position in shares of Kymera Therapeutics in the third quarter worth $61,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after buying an additional 504 shares during the period. Comerica Bank increased its holdings in Kymera Therapeutics by 13.7% in the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of Kymera Therapeutics by 7.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after buying an additional 295 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado bought a new stake in shares of Kymera Therapeutics during the 2nd quarter worth approximately $139,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.